Chemotherapy Induced Neutropenia (CIN) – Market Insights,
Epidemiology and Market Forecast-2023 Report provides an overview of the
disease and global market trends of the Chemotherapy Induced Neutropenia for
the seven major markets i.e., United States, Europe (France, Germany, Italy,
Spain, UK) and Japan, as well as rest of Europe (RoE) and rest of the world
(RoW). The Report covers the therapeutics market revenue, treatment practice
and Chemotherapy Induced Neutropenia (CIN) forecasted market share from 2017 to
2023 segmented by seven major markets. In addition, the report provides the
historical and forecasted data of incident cases at risk of Chemotherapy
Induced Neutropenia (CIN) in 10 cancer indications till 2023.
The report covers the number of patients for 10 cancer
indications (i.e. Breast Cancer, Leukemia, Prostate Cancer, Lung Cancer, Cervical
Cancer, Pancreatic Cancer, Colorectal Cancer, Ovarian Cancer, Hodgkin’s disease
and Non-Hodgkin Lymphoma), who are at risk of developing CIN as an adverse
event of the chemotherapies of respective cancers.
Neupogen (Filgrastim), developed and marketed by Amgen is
the first G-CSF approved for chemotherapy-induced neutropenia (CIN) in 1991.
Its PEGylated formulation, Neulasta was later approved in 2002. Filgrastim
i.e., Neupogen and PEGylated filgrastim (Neulasta) contribute to majority of
the market size, of CIN. However, New Chemical Entities are expected to launch
in the near future. According to Publisher, the Global Market size of CIN in
2016 was USD 3.67 Billion.
The report is built using data and information sourced from
proprietary databases, primary and secondary research and in-house Forecast
model analysis by Publisher team of industry experts.
Spanning over 132 pages “Chemotherapy Induced
Neutropenia (CIN) - Market Insights, Epidemiology and Market Forecast-2023” report covers Report Introduction,
Global Market Size of CIN in 2016, Global Market Size of CIN in 2023, Appendix.
For
more information Visit at: http://mrr.cm/Ui5
Find all Diseases Reports at: http://www.marketresearchreports.com/diseases
No comments:
Post a Comment
Note: only a member of this blog may post a comment.